Dementia screening typically starts with a short cognitive test that takes 3 to 15 minutes, administered by a primary care provider or sometimes completed at home. There is no single blood draw or brain scan that confirms dementia on its own. Instead, screening is a stepped process: a brief assessment flags potential problems, followed by deeper testing and lab work to confirm whether true cognitive decline is present and what’s causing it.
When Screening Makes Sense
The clearest reason to pursue screening is when you or someone close to you has noticed changes. Difficulty managing medications, trouble paying bills that were once routine, repeating questions in the same conversation, or getting lost in familiar places are the kinds of everyday slip-ups that warrant a formal look. A family member or close friend often spots these shifts before the person experiencing them does.
Speed of decline matters too. A slow, steady slide over months or years points toward a neurodegenerative cause like Alzheimer’s. Rapid decline over weeks could signal something more urgent, like a metabolic problem, infection, or even a brain tumor. Personality changes, such as new impulsivity or social withdrawal, sometimes indicate frontotemporal dementia. Early visual hallucinations raise suspicion for Lewy body dementia. The pattern of symptoms helps steer what comes next.
If you’re on Medicare, detecting cognitive impairment is a required component of the Annual Wellness Visit. Your provider should be checking for signs at every wellness appointment, either through direct observation, a brief test, or by asking you and your family about changes in memory and daily functioning.
What the US Preventive Services Task Force Says
The USPSTF currently gives universal screening for cognitive impairment in older adults an “I” grade, meaning there isn’t enough evidence yet to say whether routine screening of people with no symptoms does more good than harm. This doesn’t mean screening is discouraged when symptoms are present. It means that blanket testing of every older adult, regardless of complaints, hasn’t been proven beneficial at a population level. If you’re noticing cognitive changes, screening is appropriate and recommended.
Common Screening Tests
Three tools dominate primary care settings, each with different strengths.
The Mini-Cog is the quickest option. It combines a three-word recall task with a clock-drawing test and takes about 3 minutes. It works well as a first-pass filter because it’s fast and doesn’t require special training to administer. Its brevity makes it popular in busy clinics, but it can miss subtle or early-stage decline.
The Mini-Mental State Examination (MMSE) has been used for decades and tests orientation, attention, memory, language, and visual-spatial skills. It has good sensitivity, meaning it catches most people who genuinely have cognitive problems. However, it lacks specificity at commonly used cutoffs, so it can flag people who are actually fine, particularly those with lower education levels or high test anxiety.
The Montreal Cognitive Assessment (MoCA) is a 10-minute test that pushes harder on executive function, abstract thinking, and attention. It outperforms the MMSE at catching early and mild cognitive impairment. In comparative studies, the MoCA showed superior discriminative ability, with an accuracy score (AUC) of 0.87 versus the MMSE’s 0.80. The MoCA is particularly sensitive to the kind of subtle decline that shows up before full-blown dementia, making it a better choice when you or your doctor suspect something is off but symptoms are still mild.
Informant Questionnaires
Sometimes the most useful information comes from the people around you. The AD-8 is an eight-question form completed by a family member or close friend. It takes under three minutes and asks about changes in judgment, interest in hobbies, repeating questions, trouble with appliances, and similar functional shifts. At a cutoff score of two, it has 92% sensitivity for detecting dementia, meaning it catches the vast majority of true cases. Its specificity is lower (around 64%), so a positive result doesn’t mean dementia is certain. It means further evaluation is warranted. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) is a longer alternative that works similarly.
The Self-Administered Gerocognitive Examination (SAGE) takes a different approach: it’s a written test you complete yourself with pen and paper, without a clinician present. It’s available for free through Ohio State University and can be a starting point if you want to check yourself before scheduling an appointment.
Digital and Tablet-Based Assessments
A growing number of tablet-based cognitive tests are entering clinical and research settings. Platforms like Cogstate, Altoida, and TabCAT deliver tasks on a screen and can be administered in a clinic or, in some cases, at home. These tools measure things like reaction time, pattern learning, and spatial memory with more precision than a paper test can offer. Some have shown the ability to distinguish people with early Alzheimer’s-related brain changes from those without, with accuracy scores in the 0.73 to 0.91 range depending on the specific task and platform.
These digital tools are still primarily used in research and specialty clinics rather than routine primary care. They’re not yet replacements for established screening tests, but they’re increasingly being validated and may become standard options in coming years.
Ruling Out Reversible Causes
One of the most important parts of dementia screening has nothing to do with cognitive tests. Several treatable conditions can mimic dementia, and catching them changes the outcome entirely. The American Academy of Neurology recommends screening for vitamin B12 deficiency, hypothyroidism, and depression as part of any cognitive workup. These three conditions alone account for a significant share of reversible cognitive impairment.
The full list of reversible causes is broader. Medications with anticholinergic effects (common in allergy drugs, bladder medications, and some antidepressants) can cloud thinking. Alcohol or drug use, infections like urinary tract infections in older adults, and metabolic problems all belong on the list. Normal pressure hydrocephalus, a condition where fluid builds up in the brain, causes a characteristic triad of walking difficulty, urinary incontinence, and cognitive decline, and it’s treatable with a shunt. Your provider will typically order blood work including thyroid function, B12 levels, and a basic metabolic panel, and may add a CT or MRI scan of the brain to rule out structural causes like tumors or fluid buildup.
What Happens After a Positive Screen
A positive result on a screening test is not a diagnosis. It’s a signal that more detailed evaluation is needed. The next step is usually formal neuropsychological testing, a session (often 2 to 4 hours) with a neuropsychologist who evaluates memory, language, attention, executive function, and visual-spatial abilities in depth. This testing can distinguish normal aging from mild cognitive impairment from dementia, and it helps characterize which cognitive abilities are affected, which in turn helps identify the underlying cause.
Formal neuropsychological testing is especially valuable in two situations: when clinical suspicion is high but brief screening tests come back normal, and when screening reveals a problem but the pattern doesn’t clearly point to a specific type of dementia. Even when a screening test does show an abnormality, detailed testing helps map cognitive strengths and weaknesses, which is useful for planning daily life and support.
A clinical diagnosis of major neurocognitive disorder (the current diagnostic term for dementia) requires two things: significant decline in at least one cognitive domain, defined as performance falling well below expected norms, and that decline must interfere with your ability to handle everyday activities independently. Things like managing finances, taking medications correctly, driving safely, or preparing meals. If cognition has slipped but daily functioning remains intact, the diagnosis is typically mild cognitive impairment rather than dementia.
Blood Tests for Alzheimer’s Disease
Blood-based biomarker tests that measure proteins associated with Alzheimer’s, including amyloid-beta and phosphorylated tau, are now available in some clinical settings. These tests can detect Alzheimer’s-related brain changes with meaningful accuracy and are primarily used to help confirm or rule out Alzheimer’s as the cause of symptoms in people already showing cognitive decline. They can reduce the need for more invasive testing like spinal taps or expensive PET scans.
What these blood tests cannot yet do reliably is screen asymptomatic people. The evidence supporting their use as a screening tool in people without symptoms is still limited. Most validation studies have been conducted in populations of European ancestry, and how well these tests perform across diverse populations remains an open question. For now, they’re most useful as a diagnostic and triage tool once cognitive symptoms have already appeared, not as a population-wide screening measure.